Holen Sie sich die Stockscreener-App
70.97
2.62%
1.81
Schlusskurs vom Vortag:
$69.16
Offen:
$69.38
24-Stunden-Volumen:
720.99K
Relative Volume:
1.04
Marktkapitalisierung:
$3.65B
Einnahmen:
$379.25M
Nettoeinkommen (Verlust:
$-77.34M
KGV:
-44.02
EPS:
-1.6122
Netto-Cashflow:
$-27.87M
1W Leistung:
-0.66%
1M Leistung:
+2.88%
6M Leistung:
+60.17%
1J Leistung:
+63.22%
1-Tages-Spanne:
$68.95
$71.56
1-Wochen-Bereich:
$68.95
$72.98
52-Wochen-Spanne:
$36.88
$78.54
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Vergleichen Sie MIRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
70.97 | 3.55B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Is Mirum Pharmaceuticals Inc. stock safe for conservative investors2025 Performance Recap & Comprehensive Market Scan Insights - newser.com
Mirum Pharmaceuticals fosters rare liver disease collaborations at NASPGHAN 2025 - Traders Union
Will Mirum Pharmaceuticals Inc. (08D) stock benefit from mergersMarket Growth Review & Accurate Technical Buy Alerts - newser.com
Is Mirum Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Levels & High Accuracy Buy Signal Tips - newser.com
Will Mirum Pharmaceuticals Inc. see short term momentum2025 AllTime Highs & Reliable Trade Execution Plans - newser.com
Why Mirum Pharmaceuticals Inc. (08D) stock attracts HNW investorsPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Why Mirum Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Selloffs & Smart Swing Trading Techniques - newser.com
Is Mirum Pharmaceuticals Inc. (08D) stock worth buying before Fed actionProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is Mirum Pharmaceuticals Inc. stock overvalued by current metrics2025 Sector Review & Low Risk High Reward Ideas - newser.com
Will Mirum Pharmaceuticals Inc. (08D) stock keep high P E multiples2025 Biggest Moves & Precise Entry and Exit Recommendations - newser.com
(MIRM) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Mirum Pharmaceuticals: Strategic Positioning and Strong Defense Justify Buy Rating - TipRanks
Is Mirum Pharmaceuticals Inc. stock supported by strong cash flows2025 Top Decliners & Risk Controlled Daily Plans - newser.com
Mirum Pharmaceuticals to File Patent Infringement Lawsuit Against Sandoz - MarketScreener
Mirum Pharmaceuticals receives notice of generic challenge to Livmarli patents - Investing.com
A Look at Mirum Pharmaceuticals's Valuation Following Profit Surge and Raised 2025 Guidance - simplywall.st
How Mirum Pharmaceuticals Inc. (08D) stock valuation compares with sectorWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
Why Mirum Pharmaceuticals Inc. stock is popular among millennials2025 Valuation Update & Entry Point Confirmation Signals - Fundação Cultural do Pará
What analysts say about Mirum Pharmaceuticals Inc stockShort-Term Trading Alerts & High Yield Portfolio Picks - earlytimes.in
Mirum Pharmaceuticals Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Top Analyst Picks Available for Free - earlytimes.in
Mirum Pharmaceuticals drives liver disease research at NASPGHAN2025 - Traders Union
Mirum Pharmaceuticals at Stifel 2025: Optimism in Rare Disease Space By Investing.com - Investing.com Canada
Published on: 2025-11-10 20:09:07 - newser.com
Mirum Pharmaceuticals (NASDAQ: MIRM) grants 53.5K options to 11 new employees - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Will breakout in Mirum Pharmaceuticals Inc. lead to full recoveryJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2025 Earnings Call Transcript - MSN
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting® - Lelezard
Responsive Playbooks and the MIRM Inflection - news.stocktradersdaily.com
Mirum to present new data on liver disease therapies at AASLD meeting - Investing.com India
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):